BioCentury
ARTICLE | Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

July 20, 2018 5:33 PM UTC

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis.

MorphoSys and Galapagos will receive €95 million ($111.1 million) up front and are eligible for €850 million ($993.8 million) in milestones, plus double-digit royalties. MorphoSys and Galapagos will split all payments evenly...